NAD Refers Salonpas Ad Claims To FDA, FTC

Law360, New York (January 21, 2014, 4:29 PM EST) -- The National Advertising Division said Thursday that it's asking the Federal Trade Commission and the U.S. Food and Drug Administration to investigate Hisamitsu America Inc.’s claims regarding the efficacy of its Salonpas pain relief products after the company declined to participate in the NAD’s process.

Hisamitsu allegedly advertised its Salonpas brand pain relief patches and sprays as being “the strongest labeled pain reliever available without a prescription,” among other things, according to the NAD. Pfizer Consumer Healthcare, a competing manufacturer of ThermaCare over-the-counter heat wraps, had...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.